Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| B3L | Ann:Half Yearly Report Audit Review (Price Sensitive) | 15/03/18 | 0 | 79 | |||
|
|||||||
| B3L | Ann:Half Yearly Report 31 December 2017- Appendix3 (Price Sensitive) | 15/03/18 | 0 | 79 | |||
|
|||||||
| B3L | Ann:Query - Periodic Disclosure (Price Sensitive) | 27/02/18 | 0 | 66 | |||
|
|||||||
| B3L | Ann:Response to Query - Periodic Disclosure (Price Sensitive) | 27/02/18 | 0 | 66 | |||
|
|||||||
See All Discussions
NSX News